OncologyOncology/Foot & Ankle

Foot Mass - Soft Tissue Sarcoma

Oncology
Intermediate
6 min
High Yield
soft tissue sarcomafoot massbiopsy principleswide resectionMankin studyFNCLCC gradingstaginglimb salvageray amputationbelow knee amputation
6:00
Start the timer to simulate exam conditions

Foot Mass - Soft Tissue Sarcoma

Clinical Scenario

A 40-year-old male presents with a lump on his foot that he first noticed 6 months ago. It has been slowly increasing in size and has recently become mildly painful with weight-bearing. He has no significant past medical history and is an active builder.

History:

  • 6-month history of slowly enlarging lump on dorsum of right foot
  • Initially painless, now mild discomfort with weight-bearing
  • No history of trauma
  • No previous lumps or skin lesions
  • No constitutional symptoms (weight loss, night sweats, fevers)
  • Non-smoker, occasional alcohol
  • Occupation: Builder (active work)
  • No family history of cancer

Examination Findings:

  • 5 x 4 cm firm, fixed mass on dorsolateral aspect of right midfoot
  • Located deep to extensor tendons
  • Not attached to overlying skin
  • Fixed to underlying structures (does not move with tendon excursion)
  • Non-tender
  • No overlying skin changes (no ulceration, no satellite nodules)
  • Normal pulses distally
  • Intact sensation
  • Full active range of motion of ankle and toes
  • No regional lymphadenopathy (inguinal nodes impalpable)

Investigations

Laboratory Results

Imaging

Plain X-ray Right Foot:

  • Soft tissue mass visible on dorsum of foot
  • No calcification within the mass
  • No underlying bone erosion or periosteal reaction
  • No obvious bone involvement
  • Normal bone density

MRI Right Foot with Gadolinium:

  • 5.2 x 4.5 x 3.8 cm heterogeneous soft tissue mass
  • Located deep to extensor digitorum brevis, superficial to tarsal bones
  • T1: Intermediate signal, iso-intense to muscle
  • T2: Heterogeneous high signal with some areas of low signal (haemorrhage or necrosis)
  • Gadolinium: Heterogeneous enhancement with central non-enhancing areas (necrosis)
  • Margins appear well-defined but no true capsule
  • Abuts but does not invade underlying cuneiform and cuboid
  • Displaces but does not encase dorsalis pedis artery
  • No skip lesions
  • No involvement of plantar structures

CT Chest:

  • No pulmonary metastases
  • No mediastinal lymphadenopathy

Questions & Model Answers

Q

What is your differential diagnosis for this foot mass, and what features are concerning for malignancy?

Q

Describe the principles of biopsy for a suspected soft tissue sarcoma, referencing Mankin's study.

Q

The biopsy confirms high-grade undifferentiated pleomorphic sarcoma (UPS). How do you stage this tumour?

Q

What are the surgical options for this patient? Discuss limb salvage versus amputation.

Q

What is the role of radiotherapy and chemotherapy in soft tissue sarcoma?

Q

What is the prognosis for this patient and what is the surveillance protocol?


Key Teaching Points

ConceptDetail
Red FlagsDeep + >5cm + enlarging = treat as sarcoma
BiopsyMankin's principles - by treating surgeon, longitudinal, excisable tract
StagingCT Chest essential - lungs are primary met site
MarginsWide (1-2cm) for R0 resection
RadiotherapyReduces local recurrence from 50% to 15%
ChemotherapyLess effective than in bone sarcomas

Common Examiner Follow-up Questions

  1. "What is the FNCLCC grading system?"

    • French Fédération Nationale des Centres de Lutte Contre le Cancer
    • Based on: Differentiation (1-3) + Mitoses (1-3) + Necrosis (0-2)
    • Total 2-3 = Grade 1, 4-5 = Grade 2, 6-8 = Grade 3
    • Higher grade = higher metastatic risk
  2. "What is clear cell sarcoma?"

    • "Melanoma of soft parts"
    • Predilection for tendons and aponeuroses in foot/ankle
    • EWSR1-ATF1 translocation
    • S100 and HMB45 positive (like melanoma)
    • Very aggressive, poor prognosis
  3. "When would you resect pulmonary metastases?"

    • Solitary or limited number (<3)
    • Long disease-free interval (>12 months)
    • Primary tumour controlled
    • Patient fit for thoracic surgery
    • Potentially curative if R0 resection achieved